Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism

What Was Tested

Researchers studied Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism in this randomized controlled trial publication.

Surgery is the usual therapy for patients with primary hyperparathyroidism.

Who Took Part

The study group was 568 women.

The age groups tagged for this paper are middle-aged adults and older adults, women only.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The women were allocated by chance, so the Parathyroid Hormone (PTH 1-84) group and the comparison group should start out alike.

As a double-blind Parathyroid Hormone (PTH 1-84) study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Parathyroid Hormone (PTH 1-84) group a baseline to be compared against.

What Was Measured

Surgery is the usual therapy for patients with primary hyperparathyroidism.

Topics PubMed links to this paper include Aniline Compounds, Calcium, Hyperparathyroidism, Parathyroid Hormone, Phenethylamines and Propylamines.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Parathyroid Hormone (PTH 1-84) in 568 women in people with hyperparathyroidism.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1997 (The New England journal of medicine), a journal based in United States.

More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.